6505--Pharmaceutical - FdG/NaF

The Department of Veterans Affairs (VA) is seeking quotes for the supply of two radiopharmaceuticals: Sodium Fluoride and Fluorodeoxyglucose, intended for use at the Philadelphia VA Medical Center. This solicitation, numbered 36C24425Q0532, will be open until April 11, 2025, at 10:00 AM Eastern Time. The contract falls under the NAICS Code 325412, with a size standard of 1,300 employees. Interested vendors must download the solicitation and any amendments from the SAM.gov website, as no hard copies will be issued. All inquiries are to be submitted in writing via email to the designated Contract Specialist, Matthew Wright, with no phone inquiries accepted. This procurement reflects the VA's commitment to ensuring quality healthcare for veterans through the acquisition of essential medical supplies.

The document outlines a solicitation for the provision of nuclear medicine pharmaceuticals, specifically Fluorodeoxyglucose (FDG) and Sodium Fluoride (NaF), by a licensed vendor to the CMCVAMC Nuclear Medicine Department. The contractor must meet stringent regulatory requirements to ensure quality and safety in the delivery of these radiopharmaceuticals, which are essential for imaging procedures and equipment testing. Key deliverables involve timely deliveries, labeling compliance, and maintaining adequate stock levels for the medical center's needs. The contractor is required to accept returns for credit under specific conditions and provide electronic daily tracking systems for dosage. Contractual obligations include compliance with federal regulations and quality control procedures, ensuring that only new and properly sourced materials are supplied. Overall, this acquisition focuses on enhancing patient care through reliable and compliant supply chain practices in the Veterans Affairs medical facilities.

This document amends a federal solicitation related to a contract administered by the Department of Veterans Affairs, specifically the Network Contracting Office 4. The purpose of this amendment is to clarify the period of performance for the contract, which is set for one year, starting from April 14, 2025, and concluding on April 13, 2026. The amendment also instructs all offerors and bidders to acknowledge receipt of this amendment through specific methods detailed within the document. Any changes to previously submitted offers can be communicated correspondingly, provided they are received before the designated opening date. The amendment maintains all other terms and conditions of the prior agreement intact, confirming that the administrative changes do not affect the core contract terms. The document is structured clearly with identified sections for modification requests and contractor information, facilitating concise communication among involved parties.

This document serves as an amendment to a previous combined solicitation for pharmaceutical products, specifically FdG/NaF, issued by the Department of Veterans Affairs (VA). The solicitation number is 36C24425Q0532, with responses due by April 11, 2025, at 10:00 AM Eastern Time. The contracting office is located at 1010 Delafield Road, Pittsburgh, PA, with the primary point of contact being Contract Specialist Matthew Wright, who can be reached via email. The place of performance for the contract will be the Philadelphia VA Medical Center, underscoring the focus on healthcare services for veterans. The document also noted that it is not funded by the Recovery Act, and emphasizes the use of Small Business Administration (SBA) set-asides. More detailed information pertains to the product service (6505) and NAICS code (325412) associated with the pharmaceutical products being procured. This solicitation amendment signifies ongoing procurement efforts to enhance service delivery in the VA healthcare system, ensuring that veterans receive necessary pharmaceutical care.